Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution

Toxicology and Applied Pharmacology

Volumn 164, Issue 2, 2000, Pages 134-142

  Cheng, Shuk Han ^a   Lam, Wing ^a   Lee, Agnes S K ^a   Fung, Kwok Pui ^b   Wu, Rudolf S S ^a   Fong, Wang Fun ^a  

^a CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Benzo a pyrene; Doxorubicin; Lung resistance related protein; Subcellular distribution

Indexed keywords

ANTINEOPLASTIC AGENT; BENZO[A]PYRENE; CISPLATIN; COLCHICINE; CYCLOSPORIN; DOXORUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; RNA; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION;

EID: 0011036628     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2000.8903     Document Type: Article

References (41)

1. Caponigro F., French R. C., Kaye S. B. Protein kinase C: A worthwhile target for anticancer drugs. Anticancer Drugs. 8:1997;26-33.
2. Caruso J. A., Batist G. Divergent mechanisms for loss of Ah-responsiveness in benzo[a]pyrene- and adriamycin-resistant MCF-7 cells. Biochem. Pharmacol. 57:1999;1253-1263.
3. Chen C., Chin J. E., Ueda K., Clark D. P., Pastan I., Gottesman M. M. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug resistant cells. Cell. 47:1986;381-389.
4. Chin K. V., Tanaka S., Darlington G., Pastan I., Gottesman M. M. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J. Biol. Chem. 265:1990;221-226.
5. Chou T. C., Talalay P. Quantitive analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
6. Chugani D. C., Rome L. H., Kedersha N. L. Evidence that vault ribonuceloprotein particles localise to the nuclear pore complex. J. Cell Sci. 106:1993;23-29.
7. Coley H. M., Amos W. B., Twentyman P. R., Workman P. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cells. Br. J. Cancer. 67:1993;1316-1323.
8. Critchfield J. W., Welsh C. J., Phang J. M., Yeh G. C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells: Activation of P-glycoprotein as a putative mechanism. Biochem. Pharmacol. 48:1994;1437-1445.
9. Eijdems E. W., Zaman H. M., De Haas M., Versantvoort C. H. M., Flens K. J., Scheper R. J., Kamst E., Borst P., Baas F. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1537 cells. Br. J. Cancer. 72:1995;298-306.
10. Gigli M., Rasoanaivo T. W. D., Millot J. M., Jeannesson P., Rizzo V., Jardillier J. C., Arcamone F., Manfait M. Correlation between growth inhibition and intranuclear doxorubicin and 4′-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry. Cancer Res. 49:1989;560-564.
11. Goldenberg G. J., Wang H., Blair G. W. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and resistant P388 leukemia. Cancer Res. 46:1986;2978-2983.
12. Hamill D. R., Suprenant K. A. Characterisation of the sea urchin major vault protein: A possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev. Biol. 190:1997;117-128.
13. Hatcher E. L., Alexander J. M., Kang Y. J. Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells. Biochem. Pharmacol. 53:1997;747-754.
14. Herrmann C., Kellner R., Volknandt W. Major vault protein of electric ray is a phosphoprotein. Neurochem. Res. 23:1998;39-46.
15. Ivy S. P., Tulpule A., Fairchild C. R., Acerbuch S. D., Myers C. E., Nebert D. W., Baird W. M., Cowan K. H. Altered regulation of p-4501A1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J. Biol. Chem. 263:1988;19119-19125.
16. Izquierdo M. A., van der Zee A. G., Vermorken J. B., van der Valk P., Belien J. A., Giaccone G., Scheffer G. L., Flens M. J., Pinedo H. M., Kenemans P. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst. 87:1995;1230-1237.
17. Izquierdo M. A., Scheffer G. L., Flens M. J., Giaccone G., Broxterman H. J., Meijer C. J., van der Valk P., Scheper R. J. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumours. Am. J. Pathol. 148:1996;877-887.
18. Kartner N., Evernden-Porelle D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 316:1985;820-823.
19. Kickhoefer V. A., Rajavel K. S., Scheffer G. L., Dalton W. S., Scheper R. J., Rome L. H. Vaults are up-regulated in multidrug-resistant cancer cell lines. J. Biol. Chem. 273:1998;8971-8974.
20. Komarov P. G., Shtil A. A., Holian O., Tee L., Buckingham L., Mechetner E. B., Roninson I. B., Coon J. S. Activation of the LRP (lung resistance-related protein) gene by short-term exposure of human leukemia cells to phorbol ester and cytarabine. Oncol. Res. 10:1998;185-192.
21. Kong L. B., Siva A. C., Rome L. H., Stewart L. Structure of the vault, a ubiquitous cellular component. Structure. 7:1999;371-379.
22. Laurencot C. M., Scheffer G. L., Scheper R. J., Shoemaker R. H. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant cancer cell lines. Int. J. Cancer. 72:1997;1021-1026.
23. Lechevrel M., Casson A. G., Wolf C. R., Hardie L. J., Flinterman M. B., Montesano R., Wild C. P. Characterization of cytochrome P450 expression in human oesophageal mucosa. Carcinogenesis. 20:1999;243-248.
24. List A. F., Spier C. S., Grogen T. M., Johnson C., Roe D. J., Greer J. P., Wolff S. N., Broxterman H. J., Scheffer G. L., Scheper R. J., Dalton W. S. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 87:1996;2464-2469.
25. Manfait M., Alix A. J. P., Jeannesson P., Jardillier J. C., Theophanides T. Interaction of adriamycin with DNA as studied by resonance Raman spectroscopy. Nucleic Acids Res. 10:1982;3803-3816.
26. Noel G., Peterson C., Trouet A., Tulkens P. Uptake and subcellular localisation of daunorubicin and adriamycin in cultured fibroblast. Eur. J. Cancer. 14:1978;363-368.
27. Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D., Roninson I. B. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 87:1990;7160-7164.
28. Obi F. O., Billett M. A. Preferential binding of the carcinogen benzo[a]pyrene to proteins of the nuclear matrix. Carcinogenesis. 12:1991;481-486.
29. Pall G., Spitaler M., Hofmann J., Thaler J., Ludescher C. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia. 11:1997;1067-1072.
30. Rome L. H., Kedersha N. L., Chugani D. C. Unlocking vaults: organelles in search of a function. Trends Cell Biol. 1:1991;47-50.
31. Scheper R. J., Broxterman H. J., Scheffer G. L., Kaaijk P., Dalton W. S., van Heijningen T. H., van Kalken C. K., Slovak M. L., de Vries E. G., van der Valk P., Meijer C. J. L. M., Pinedo H. M. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53:1993;1475-1479.
32. Scheffer G. L., Wijngaard P. L. J., Flens M. J., Izquierdo M. A., Slovak M. L., Pinedo H. M., Meijer C. J. L. M., Clevers H. C., Scheper R. J. The drug resistance-relted protein LRP is the human major vault protein. Nature Med. 1:1995;578-582.
33. Schuurhuis G. J., van Heijningen T. H. M., Cervantes A., Pinedo H. M., de Lange J. H. M., Keizer H. G., Broxterman H. J., Baak J. P. A., Lankelma J. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br. J. Cancer. 68:1993;898-908.
34. Shen D. W., Cardarelli C., Hwang J., Cornwell M., Richert N., Ishii S., Pastan I., Gottesman M. M. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, doxorubicin, or vinblastine show changes in expression of specific proteins. J. Biol. Chem. 261:1986;7762-7770.
35. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimeteric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
36. Stein U., Walther W., Lemm M., Naundorf H., Fichtner I. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int. J. Cancer. 72:1997;885-891.
37. Versantvoort C. H., Withoff S., Broxterman H. J., Kuiper C. M., Scheper R. J., Mulder N. H., de Vries E. G. Resistance-asociated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int. J. Cancer. 61:1995;375-380.
38. Volm M., Mattern J., Koomagi R. Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance. Anticancer Drugs. 8:1997;931-936.
39. Volm M. Multidrug resistance and its reversal. Anticancer Res. 18:1998;2905-2918.
40. Yeh G. C., Lopaczynska J., Poore C. M., Phang J. M. A new functional role for P-glycoprotein: Efflux pump for benzo(a)pyrene in human breast cancer MCF-7 cells. Cancer Res. 52:1992;6692-6695.
41. Zaman G. J., Flens M. J., van Leusden M. R., de-Haas M., Mulder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA. 91:1994;8822-8826.